A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate

Inclusion Criteria: * Healthy male or female ≥ 18 and ≤ 45 years of age * Agrees not to donate blood during the course of the trial. * Signed written informed consent provided. * Available to participate for the study duration. Exclusion Criteria: * History of allergic reactions following any vaccination. * Involvement in drug or other vaccine trial within four weeks prior to the trial. * Acute illness within four weeks prior to the trial. * Presence of fever at the time of vaccination, i.e. body temperature (by axillary) \> 37.5 C. * Presence of any chronic illness/disease including diabetes mellitus, tuberculosis, leprosy, epilepsy and hypertension determined by medical history or examination. * Persons on systemic corticosteroids, immunomodulators or anticoagulants within four weeks prior to vaccination. * Persons with a history of allergic manifestations requiring treatment with injectable antihistamines, adrenaline or steroids. * Pregnancy. Women should not be pregnant, lactating, or planning pregnancy throughout the study period. A urinary pregnancy test (immuno-chromatography) will be performed for all women of child-bearing potential at entry and prior to each vaccination. Adequate contraception throughout the study should be used if applicable. * Sexually active woman not using contraceptives. * Current smoker ( ≥ 20 cigarettes/day). * History of malaria: persons with a known history of malaria or with positive markers for antibodies to malaria parasite by IFA and/or ELISA. * History of residing in a malaria endemic region or malaria exposure (travel) within last two years. * Abnormal hematology and clinical chemistry considered to be clinically significant. * Abnormal urine routine test considered to be clinically significant * Persons with positive markers for HBV (HBsAg) and/or HCV (Anti-HCV) infection.